# Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

> **NCT03248128** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 906 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** FF/VI via ELLIPTA DPI
- **DRUG:** FF via ELLIPTA DPI

## Key facts

- **NCT ID:** NCT03248128
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-20
- **Primary completion:** 2022-03-21
- **Final completion:** 2022-03-21
- **Target enrollment:** 906 (ACTUAL)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03248128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03248128, "Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03248128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*